Medical treatment of brain tumours, particularly glioma, with an emphasis on novel drug evaluation for glioblastoma
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Oncologist. 2018 Sep 28;:
PLoS One. 2018;13(8):e0202860
Significance of treatment response when managing patients with primary central nervous system lymphoma.
Leuk Lymphoma. 2018 Jul 03;:1-9
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.
Neuro Oncol. 2018 Apr 20;:
Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Neuro Oncol. 2018 Apr 05;:
Neuro Oncol. 2018 Mar 28;:
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Eur J Cancer. 2018 Mar 20;94:168-178
Oculoleptomeningeal amyloidosis secondary to the rare Transthyretin c.381T>G (p.Ile127Met) mutation.
World Neurosurg. 2017 Dec 22;:
Curr Oncol. 2017 Dec;24(6):374-382
Can J Neurol Sci. 2017 Dec 18;:1-7
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Medical Director, Gerry and Nancy Pencer Brain Tumour Centre
Kirchmann Family Chair in Neurooncology Research, Princess Margaret Hospital